Home / Market News / $ARCT

$ARCT news and market catalysts

The 10 most recent market catalysts affecting $ARCT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

10 catalysts 3 high impact 6 bullish 1 bearish Biotechnology
Nov 16, 2026 Corporate Catalyst Bullish Impact 75
Arcturus Therapeutics Secures $50 Million Investment From Meiji Seika Pharma
Arcturus Therapeutics secured a $50 million investment from Meiji Seika Pharma, which is tied to an expansion of their existing collaboration. This capital injection is a significa…
Nov 5, 2026 Corporate Catalyst Neutral Impact 75
Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress
Arcturus Therapeutics reported its Q3 2026 financial results, which is a routine disclosure, but the key catalyst lies in the pipeline updates. The announcement of encouraging Phas…
Oct 14, 2026 Corporate Catalyst Neutral Impact 75
Transcript: Arcturus Therapeutics Q2 2026 Earnings Conference Call
Arcturus Therapeutics' Q2 2026 earnings call provided updates on its rare disease pipeline, ARCT032 for cystic fibrosis and ARCT810 for OTC deficiency, with both programs showing a…
Oct 9, 2026 Corporate Catalyst Bullish Impact 65
Leerink Partners Maintains Outperform on Arcturus Therapeutics, Raises Price Target to $19
Leerink Partners, through analyst Lili Nsongo, maintained an 'Outperform' rating on Arcturus Therapeutics and raised its price target from $13 to $19. This upgrade signals increase…
Sep 24, 2026 Corporate Catalyst Bullish Impact 85
Why Is Arcturus Therapeutics Stock Gaining Thursday?
Arcturus Therapeutics released a series of positive updates, including favorable interim Phase 2 results for ARCT-810, indicating safety and efficacy in managing OTC deficiency. Co…
Sep 24, 2026 Corporate Catalyst Bullish Impact 65
Citigroup Upgrades Arcturus Therapeutics to Buy, Raises Price Target to $20
Citigroup analyst Yigal Nochomovitz upgraded Arcturus Therapeutics (ARCT) from Neutral to Buy and raised the price target from $8 to $20. This is a significant positive catalyst fo…
Sep 23, 2026 Corporate Catalyst Bullish Impact 75
Arcturus Therapeutics Says ARCT-810 Generally Safe And Well Tolerated, Demonstrating Encouraging Activity Across Key Urea Cycle Biomarkers In Ongoing Phase 2 Study
Arcturus Therapeutics reported encouraging interim Phase 2 results for ARCT-810, a drug targeting ornithine transcarbamylase (OTC) deficiency. The filing highlights the drug's safe…
Sep 23, 2026 Corporate Catalyst Bullish Impact 85
Arcturus Therapeutics Announces Interim Phase 2 Results From ARCT-810 In OTC Deficienc And Introduces LUNAR 2.0
Arcturus Therapeutics released several significant updates. The interim Phase 2 results for ARCT-810 in OTC deficiency were positive, showing safety, tolerability, and encouraging …
Sep 18, 2026 Corporate Catalyst Neutral Impact 55
Arcturus Therapeutics To Present Overview Of ARCT-810 Phase 2 Clinical Program For Ornithine Transcarbamylase Deficiency And Arcturus’ mRNA Liver Therapeutics Platform On Sept. 23
Arcturus Therapeutics is holding a virtual presentation on September 23, 2026, to provide an overview of its ARCT-810 Phase 2 clinical program for Ornithine transcarbamylase (OTC) …
Aug 6, 2026 Corporate Catalyst Bearish Impact 80
Arcturus Therapeutics Q2 EPS $(0.84) Beats $(1.00) Estimate, Sales $2.959M Miss $3.199M Estimate
Arcturus Therapeutics announced its Q2 earnings, revealing a mixed financial picture. While the company managed to beat analyst estimates for EPS, reporting a loss of $(0.84) again…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.